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Abstract: Depression remains a challenge in the field of affective neuroscience, despite a steady research progress. Six 
out of nine basic antidepressant mechanisms rely on serotonin neurotransmitter system. Preclinical studies have demon-
strated the significance of serotonin receptors (5-HT1-3,6,7), its signal transduction pathways and classical down stream tar-
gets (including neurotrophins, neurokinins, other peptides and their receptors) in antidepressant drug action. Serotonergic 
control of depression embraces the recent molecular requirements such as influence on proliferation, neurogenesis, plas-
ticity, synaptic (re)modeling and transmission in the central nervous system. The present progress report analyses the 
credibility of each protein as therapeutically relevant target of depression. In vivo interaction studies and knockout models 
which identified these targets are foreseen to unearth new ligands and help them transform to drug candidates. The impor-
tance of the antidepressant assay selection at the preclinical level using salient animal models/assay systems is discussed. 
Such test batteries would definitely provide antidepressants with faster onset, efficacy in resistant (and co-morbid) types 
and with least adverse effects. Apart from the selective ligands, only those molecules which bring an overall harmony, by 
virtue of their affinities to various receptor subtypes, could qualify as effective antidepressants. Synchronised modulation 
of various serotonergic sub-pathways is the basis for a unique and balanced antidepressant profile, as that of fluoxetine 
(most exploited antidepressant) and such a profile may be considered as a template for the upcoming antidepressants. In 
conclusion, 5-HT based multi-targeted antidepressant drug discovery supported by in vivo interaction studies and knock-
out models is advocated as a strategy to provide classic molecules for clinical trials.  
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DEPRESSION: DIAGNOSIS AND PHARMACOL-
OGICAL PERSPECTIVE 
  Antidepressant drug discovery has been a complex task 
owing to incomplete understanding of neurobiological basis 
of depression. Continuous identification of new biomarkers 
and proteins has desperately given shape to the neural picture 
of this group of disorder. However no single molecular target 
can be finalized as an ultimate therapeutic strategy. Depres-
sion is classified under mood disorder and has many sub-
types. Identification of symptom clusters (vegetative, cogni-
tive, impulse control behavioural and somatic) have visual-
ised depression as a syndrome [290]. Though diagnostic cri-
teria [9] has been continuously subjected to refinement, inci-
dence of different overlapping symptoms and subtypes (their 
neural correlates), co-morbidity with other psychiatric [80, 
248] and /or terminal illnesses [84,147,197] obscured the 
treatment lines. As a result, management of depression has 
been merely symptomatic, demanding poly-pharmacy and/or 
chronic drug therapy. Intensive research at both preclinical 
and clinical levels has still left us with treatment regimen 
offering patient recognizable improvement only after several 
weeks of treatment [3, 11, 30, 224]. Such a scenario encour-
ages new drug discovery aimed at producing new molecules 
with faster onset and reduced tolerance. Identification of 
various neuronal targets and screening of molecules from 
different chemical classes lead drug discovery programs to 
launch a wide variety of drugs (with different pharmacoki- 
netic profiles). Unravelling the complex neural circuitry of 
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depression should essentially run in parallel, to fine tune the 
existent antidepressant drug discovery programs. Superfi-
cially, harmony among neurotransmitter systems is expected 
from an ideal antidepressant. The presently available drugs 
mainly exploit the amine hypothesis of depression, principal 
locus of action being the serotonergic and/or norepinephrine 
neuron and with a secondary importance to the dopamine 
neuron.  
  The antidepressant mechanisms of drug action have been 
channelled down to nine ‘pharmacological routes’ [332]. Six 
of the nine basic antidepressant mechanisms involve the se-
rotonergic system and are explained as follows (Fig. 1). The 
selective serotonin reuptake inhibitors (SSRIs), serotonin 
norepinephrine reuptake inhibitors (SNRIs) and serotonin 
antagonist and reuptake inhibitors (SARI) share a common 
mechanism of inhibiting the serotonin trasporter. SARIs, 
inaddition have 5-HT2 receptor antagonistic property which 
reduces the side effects associated with the treatment. 
Noradrenergic and specific serotonergic antidepressants 
(NaSSA), apart from 2 receptor blockade, also antagonize 
5-HT2 and 5-HT3 receptors. Monoamine oxidase (MAO) 
inhibitors prevent degradation of 5-HT, compensating for the 
decrease in synaptic 5-HT observed in depression. Serotonin 
reuptake enhancers (SREs) which possess a reverse mecha-
nism to that of reuptake inhibitors, have lead to new way of 
antidepressant action. As an additional mechanism, they de-
crease the susceptibility of 5-HT to MAO. The effects on 5-
HT receptor subtypes not only reduce the side affects associ-
ated with antidepressant treatment, but also inspired us to 
check whether these receptors can influence the disorder 
itself. Present developments in the fields of molecular phar-
macology and biotechnology revealed the role of gene acti-216    Current Neuropharmacology, 2008, Vol. 6, No. 3 Rajkumar and Mahesh 
vation/suppression, protein expression, neuronal plasticity, 
and neurogenesis and various other inter-linked complex 
phenomenon associated with behavioural and neurochemical 
states of depression. This review updates the identified and 
probable neuronal targets of depression mainly pertaining to 
the 5-HT neurotransmitter system and attempts to highlight 
the significance of knockout models and interaction studies 
in both identifying new targets and screening specific ligands 
(acting directly/indirectly on the serotonergic system) for 
antidepressant prospects. 
SEROTONERGIC SYSTEM AS DIRECT ANTIDE-
PRESSANT DRUG TARGET 
  Several reviews have recognized the pivotal status of 
serotonergic system in depression and antidepressant drug 
action [25, 270, 310]. 5-HT as a central dogma of depres-
sion, is involved in synaptic plasticity, focal and/global neu-
rogenesis [224] and many other intricate neurogenetic 
mechanisms [146,164,167]. The preclinical studies which 
attempted to clarify the role of serotonergic receptors, the 
secondary functional proteins and various other factors in-
volved in control of depression are henceforth discussed. 
5-HT1A RECEPTOR 
  This somatodedritic autoreceptor in the raphae nuclei 
[240,258] influences neuronal firing, 5-HT synthesis and 
release [29, 126,134,156]. The presence of postsynaptic 5-
HT1A receptors in the limbic structures viz. hippocampus, 
amygdala and frontal cortex (of rats and primates) [14] is 
suggestive of their role in depression [45]. 8-hydroxy-2-(di-
n-propylamino)tetralin (8-OH-DPAT), a selective 5-HT1A
agonist induces hypothermia in mice [99] and rats [100]. 
Many interaction studies employed 8-OH-DPAT to examine 
the 5-HT1A mediated antidepressant effects of test substances 
[47, 176, 72, 36]. Adenylate cyclase inhibition assay in rat 
hippocampal membranes vaguely predicted that antidepres-
sant-like effects of 8-OH-DPAT (and buspirone) are medi-
ated by postsynaptic action involving the serotonergic sec-
ond messenger transduction in hippocampus [227]. 8-OH-
DPAT is also known to influence dopamine release [4,135]. 
Fig. (1). Schematic representation of different antidepressant mechanisms at the serotonergic synapse. The diagram depicts only those possi-
ble sites of action which have been associated with the molecular basis of depression till date. The SSRIs, SNRIs and SARIs inhibit 5-HT 
reuptake by acting on the transporter. SARIs also block the postsynaptic 5-HT2 receptors. MAO inhibitors prevent 5-HT breakdown thereby 
increasing the synaptic concentrations. NaSSAs (2 antagonists) block postsynaptic 5-HT2 and 5-HT3 receptors. SREs, enhance the presynap-
tic 5-HT uptake and also prevent the susceptibility of 5-HT to MAO. 
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Involvement of 5-HT1A receptors per se has been evidenced 
in various interaction studies in different models of depres-
sion. Agonists of 5-HT1A receptor were shown to exhibit 
antidepressant-like effects in rodent forced swim test (FST) 
[234, 281, 323], discriminative taste aversion test [175], 
learned helplessness behaviour test in rats [96], and in bul-
bectomised rats [204]. Flesinoxan, a specific 5-HT1A agonist 
has exhibited antidepressant-like effects in three models of 
depression viz. FST, 8-OH-DPAT induced hypothermia and 
olfactory bulbectomy [63]. Altered function of 5-HT1A re-
ceptors was reported in olfactory bulbectomised rats, a 
model of chronic depression [106]. Microdialysis study in 
rats indicated that antidepressant-like effects of serotonergic 
drugs were potentiated by 5-HT1A autoreceptor blockade 
[260]. 5-HT1A function is also involved in effectiveness of 
electroconvulsive shock treatment as observed from and hy-
pothermic responses in rats [329] and electrophysiological 
analysis of rat hippocampal slices [139]. Normalization of 5-
HT synthesis was associated with antidepressant-like effect 
of chronic buspirone (5-HT1A partial agonist) treatment 
[320]. This has emphasized the role of 5-HT1A receptor in 
the pathophysiology of depression, adhering to the mono-
amine theory. Faster onset was evident when SSRIs and 5-
HT1A antagonists were combined [11,61,62] in giving the 
first set of clues to 5-HT1A receptor involved in SSRI drug 
action. Furthermore, it has been found that antidepressant-
like effects of SSRIs were mediated by the activation of 5-
HT1A receptors [125,295] which alter the responsiveness of 
receptor-mediated G-protein-coupled inwardly rectifying 
potassium (GIRK) currents [59]. 5-HT1A knockout mice ex-
hibited decreased baseline immobility in forced swim and 
tail suspension tests (TST) [120, 203] indicating the pivotal 
role of this receptor, in depression. Only under chronic stress 
conditions, the 5-HT1A receptor mRNA is modulated by 
chronic antidepressant treatment, indicating the occurrence 
of multiple pathways associated with the interaction of stress 
and drug treatment [1]. Thus, modulating 5-HT1A receptor is 
definitely beneficial in depression, providing in addition, a 
faster onset of action. 
5-HT1B RECEPTOR 
  It is a presynaptic heteroreceptor [269,268] expressed in 
nucleus accumbens, caudate putamen, dorsal raphe nucleus 
and some cortical areas [42, 269]. In guinea pigs the 5-HT1B
mRNA was shown to be widely distributed throughout the 
brain, especially in the striatum, nucleus accumbens, olfac-
tory tubercle, cortex, hypothalamus, hippocampal formation, 
amygdala, thalamus, dorsal raphe and cerebellum [33]. RU 
24969, a 5HT1B agonist was shown to reduce the hippocam-
pal 5-HT efflux [194] and blockade of presynaptic 5-HT1B
receptors enhanced the SSRI’s induced 5-HT release in rats 
[68]. Moreover fluoxetine reversibly reduced 5-HT1B mRNA 
in rat dorsal raphae nucleus [10, 226] suggesting the possible 
influence of 5-HT1B receptor on depressive states. The anti-
depressant-like effects of venlafaxine, an SNRI, are likely to 
involve 5-HT1B receptors [256]. Following the aforesaid ob-
servations, antagonists of 5-HT1B receptor were screened for 
antidepressant potential. GR 127935, a non-selective 5-HT1B
antagonist, reversed the antidepressant-like effects of par-
oxetine [92] and was inactive in mice FST [296]. On the 
contrary, the molecule advanced the onset of antidepressant-
like effects of fluoxetine in rat schedule induced polydipsia 
test [128]. A study based on thermoregulatory responses 
indicates the existent functional interaction between 5-HT1B 
and 5-HT1A receptors [91]. Studies with knockout mice have 
shown that presynaptic receptors limit the ventral hippocam-
pal 5-HT release, following the chronic paroxetine treatment 
in mice [90, 186]. 5-HT1B deletion failed to affect the base-
line immobility but increased sensitivity to fluoxetine in TST 
[203] and paroxetine was inactive in knockout mice [90]. 
Among the 5-HT1B knockout mice, females demonstrated 
higher baseline levels of hippocampal 5-HT depletion which 
was reasoned as sex-linked disinhibition [145]. Presently, 5-
HT1B receptor (originally found only in rodents) was re-
ported to be expressed in human brain [27, 312, 313] and 
increased 5-HT1B mRNA was associated with bipolar disor-
der [172]. In a nutshell, preclinical testing of 5-HT1B ligands 
has left us with inconclusive results whereas knockout stud-
ies indicated that antagonism of 5-HT1B receptor may help 
antidepressant drug action. Thus, co-localization with 5-
HT1A subtype in key regions involved in depression was the 
only feature linking its etiological role. 
5-HT1D RECEPTOR 
  This sparsely distributed receptor is co-localized with 
that of 5-HT1B receptor [41,42], in olfactory tubercle, en-
torhinal cortex, dorsal raphe, cerebellum, mesencephalic 
trigeminal nucleus and in the trigeminal ganglion [33]. 
LY393558, a nonselective 5-HT1B/1D antagonist increases the 
extracellular 5-HT levels in guinea pig hypothalamus and rat 
brain [211]. None of the selective 5-HT1D ligands have found 
its use in depression and hence 5-HT1D receptor is highly 
improbable as a neuronal target. However, while designing a 
prospective antidepressant, 5-HT1D antagonism would be 
desirable to facilitate faster onset [270].
5-HT2A RECEPTOR 
  This subtype is found in cell bodies and processes of neu-
rons in the hippocampus, amygdala, striatum, olfactory 
structures. Their presence in glial structures is expected to 
have functional implications [328]. These receptors are co-
localized (80%) with 5-HT1A receptors and their mRNA is 
expressed in the rat and mouse prefrontal cortex [8]. Antide-
pressants of almost all pharmacological classes predomi-
nantly down-regulate 5-HT2A receptors [98, 243] through 
various mechanisms [302], inspiring us to consider this re-
ceptor as a potential target. Assessment of various serotoner-
gic agents in differential-reinforcement-of-low-rate 72-sec 
behaviour in rats, has lead to a hypothesis that both 5-HT1A
and 5-HT2 receptors (agonism of 5-HT1A receptor and an-
tagonism of 5-HT2 receptor) are clinically significant to arbi-
trate antidepressant effects of drugs [191]. Supporting this 
hypothesis, it has been demonstrated that chronic corticose-
trone treatment induces depression-like behavioural manifes-
tationsinrodentswithdecreased 5-HT1A and increased 5HT2A
receptor binding [83]. Chronic antidepressant treatment al-
ters 5-HT2A (and 5-HT2C) mediated hyperthermia in Fawn-
Hooded rats (genetic model of depression) [13]. Antisense 
oligonucleotide induced 5-HT2A receptor down-regulation is 
sufficient to achieve antidepressant-like effects in mice and 
enhances psychomotor activity. BDNF, a trophic factor (dis-
cussed henceforth) has been linked with 5-HT2A receptors 218    Current Neuropharmacology, 2008, Vol. 6, No. 3 Rajkumar and Mahesh 
(Fig.  2). The antidepressant-like effects of desipramine in 
bulbectomised rats are correlated with decrease in 5-HT2A
receptors of frontal cortex [218]. In mouse FST, antidepres-
sant-like effects of imipramine and desipramine can be partly 
attributed to antagonism of 5-HT2A receptors [255]. The 
norepinephrine activity due to SSRI and 5-HT2A antagonism 
is expected to provide benefit in affective disorders [292]. 
Drugs with selectivity to the 5-HT2A receptor could be used 
to manage certain symptoms of depression [280], if not all. 
Specific 5-HT2A receptor antagonists down-regulate BDNF 
mRNA expression in rat hippocampus and neocortex [307]. 
Further, the activation of 5-HT2A receptor has a beneficial 
effect on 5-HT induced de novo BDNF mRNA synthesis and 
this is mediated by a calcium and protein kinase-dependent 
pathway [206]. The direct role of 5-HT2A receptor in depres-
sion and facilitatory effects on SSRI action are well reported 
in the literature [45, 251]. The criterion of 5-HT2A antago-
nism for antidepressant action has triggered the consideration 
of experiments screening 5-HT2A antagonistic potentials in 
the test batteries for new compounds. Many selective 5-HT2A
antagonists, namely, HT-90B [138, 305], YM-992 [293], 
EMD 281014 [238] and M100907 [192], have shown antide-
pressant-like outcomes in animal models. However lack of 
adequate data from knockout studies have made the in-
volvement of 5-HT2A receptors in depression questionable. 
5-HT2C RECEPTOR (Previously 5-HT1C Receptor) 
  The pharmacological equivalence of 5-HT1C with 5-HT2C
receptor has lead to a change in nomenclature to the latter 
[249]. Studies on 5-HT2C  receptor distribution (the intial 
studies on distribution reported as 5-HT1C) in rat CNS, re-
vealed that this receptor is abundant in the anterior olfactory 
nucleus, medial and intercalated amygdaloid nuclei, hippo-
campus layers CA1 to CA3, latero-dorsal and lateral genicu-
late thalamic nuclei, caudate-putamen and several areas of 
the cortex [54, 127, 207, 212, 249]. The aforementioned 5-
HT2C receptor locations were consistent in rats and mice; 
most of these the areas being involved in depression. The 
first set of evidences linking this receptor and depression 
originated when antidepressants of different chemical classes 
mianserin [173, 239] and imipramine [35,142] were linked to 
depressive states in rats. The functional interaction with 5-
Fig. (2). A simplified schematic representation of cellular events involving the neuronal metabotropic 5-HT receptors associated with depres-
sion. 5-HT2,6,7 subtypes are post-synaptic receptors, whereas 5-HT1A is a somatodendritic autoreceptor. To simplify the cellular events, all the 
receptors (somatodendritic and post-synaptic) have been depicted in a single diagram. The 5-HT1, 6, 7 and 5-HT2 receptors through cAMP-PK 
and IP3–Ca
2+ dependent protein kinase secondary messenger systems influence CREB.  The agonists of 5-HT6, or the antagonists of 5-HT7
facilitate glutamate release. Increase in extracellular concentration of glutamate activates BDNF through AMPA receptors. BDNF and TrkB 
are target genes for CREB (transcription factor). BDNF in turn activates Arc. Altered expression of BDNF, CREB, TrkB and Arc are of po-
tential benefit in depression. (Based on references [77] and [230]). 
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HT1A receptors [22] may be critical for the antidepressant-
like effects [21, 143]. Clorgyline treatment significantly re-
duces [
3H] mesulergine binding in rat hypothalamus and 
striatum which is suggestive of the involvement of 5-HT2C
receptors in the clinical efficacy [40]. High affinity selective 
agonists, Ro 60-0175 and Ro 60-0332 have been proved ef-
ficacious in various rodent (rat) models of depression viz. 
stress induced anhedonia [216],olfactory bulbectomy in-
duced passive avoidance, operant tasks, and electroencepha-
lographic studies [141, 193], and in FST [60]. In Fawn-
Hooded rats short-term lithium treatment enhances 5-HT 
concentrations at postsynaptic 5-HT2C receptor sites [12]. 
Amidst the various mechanisms behind the antidepressant 
effect fluoxetine, a competitive and reversible antagonism at 
5-HT2C receptor was reported [48, 229] . Selective 5-HT2C
receptor agonists WAY 161503, RO 60-0175 and RO 60-
0332 decreased immobility and increased swimming in 
modified rat FST [60]. In addition, effects of fluoxetine were 
blocked by SB 206533 (a selective 5-HT2C antagonist) and 
synergized by selective agonist, RO-60-1075 [55] indicating 
that 5-HT2C receptor has significant implication on therapeu-
tic effects of antidepressants. Hence, it is observed that 
agonistic effects at 5-HT2C may be beneficial in depression. 
5-HT3RECEPTOR 
  The electrophysiologically characterized 5-HT3 receptors 
[245] are found in median raphae, hypothalamus, hippocam-
pus, amygdala [148, 149, 161, 316], which and neural corre-
lates of depression. Several preclinical (behavioural, neuro-
chemical and genetic) investigations have provided evi-
dences linking 5-HT3 receptors and depression. Serotonin 
type-3 receptor antagonists (5-HT3 RAs) reverses escape the 
deficits in rat learned helplessness test [195], a sensitive an-
tidepressant screening method. Antidepressants such as 
fluoxetine [82], imipramine, phenelzine and iproniazid [81] 
inhibit the 5-HT current mediated by 5-HT3 receptor in rat 
nodose ganglia. Antidepressant drugs that increase 5-HT 
release through a 5-HT3 mechanism, modulates noradrena-
line levels [214]. Selective 5-HT3 receptor antagonist ondan-
setron alters local cerebral glucose utilization (LCGU) in the 
rat median raphe [210], potentiated anti-immobility effects 
of SSRI’s [255] indicating the role played by 5-HT3 recep-
tors in depression. In mice FST, it has been observed that 
antidepressant-like effect of reuptake inhibitors is associated 
with potassium ion (K
+) - channel linked 5-HT3 receptors 
[38, 105, 257]. Though studies contradicting the aforemen-
tioned concept have been reported [34, 35, 132, 176], knock-
out mice have exhibited sex dependent differences of depres-
sive states in FST [26]. Other studies with 5-HT3 receptor 
antagonists such as ICS 205-930 [222], MDL 72222 [153] 
and tropisetron [39] indicate the significance of 5-HT3 recep-
tors in depression. Recently, research carried out in our labo-
ratory revealed antidepressant-like effects of a substituted 
naphthyridine carbonitrile [185] which possessed a pA2value 
comparable to ondansetron in tissue based assay [184]. The 
antidepressant-like effects of chronic ondansetron were 
demonstrated in a battery of rodent assays and involvement 
of post-synaptic 5-HT3 receptor was speculated [252]. The 5-
HT3 antagonism which was known to alleviate the side ef-
fects of antidepressant treatment is now being considered to 
compliment drug action.  
5-HT6 RECEPTOR 
  Studies using various biochemical techniques such as 
histochemistry, polymerase chain reaction and northern blot 
have elucidated the undoubted presence of these receptors in 
a list of depression related neural structures (limbic system), 
nucleus accumbens, olfactory tubercle, hippocampus and 
hypothalamus [94, 215, 263, 319], with an apparent co-
localisation with 5-HT2A/2C receptors in rat striatum [318]. 
Apart from cloning, functional and binding characterization 
[31, 284], the receptor binding affinities with various antide-
pressants have been studied [215]. Hence this adenlyl cy-
clase-cAMP coupled receptor [263, 272] is now viewed as a 
prospective target for antidepressant drug action. Interaction 
studies with various selective 5-HT6 ligands in different as-
say systems have been carried out to study the effects on 
depression. The expressions of phospho-Ser845-GluR1 and 
c-fos mRNA (in striatum and cerebral cortex) are enhanced 
by administration of fluoxetine or 2-ethyl-5-methoxy-N,N-
dimethyltryptamine (EMDT), a 5-HT6 receptor agonist. SB 
271046, a selective 5-HT6 antagonist though inactive when 
administered alone, is found to reverse the stimulatory ef-
fects of fluoxetine and EMDT. The compound also reverses 
the antidepressant-like effects of fluoxetine and EMDT in 
mice TST [291]. In contrast to the aforesaid activity, SB-
399885 (selective 5-HT6 receptor antagonist) has demon-
strated anti-immobility effects in forced swim (in both rats 
and mice) and TST (in mice) without influencing motor co-
ordination and behaviour. However the antidepressant-like 
effects are said to be mediated by non serotonergic mecha-
nism [321]. Intra-hippocampal administration of SB 258585 
(5-HT6 receptor antagonist), has shown anti-immobility ef-
fects in rat FST [289]. The selective 5-HT6 receptor agonist 
LY-586713, up-regulates (with a bell-shaped dose response) 
hippocampal BDNF mRNA expression and increases the 
cortical and hippocampal levels of activity regulated, cy-
toskeletal-associated protein (Arc). Pre-treatment with the 
selective 5-HT6 receptor antagonist SB-271046 completely 
blocks this up-regulation in BDNF and attenuates Arc levels 
in the respective regions (observed at active dose level of 
LY-586713). BDNF up-regulation has been through sequen-
tial activation of cAMP and CREB (transcription factor for 
BDNF gene) or due to increase in extracellular glutamate 
induced by 5-HT6 receptor activation (Fig. 2). Similarly, the 
increase in Arc mRNA expression could be linked to cAMP, 
glutamate and BDNF [70]. In summary, these reports con-
firm the beneficial effects of 5-HT6 receptor stimulation in 
managing depression. 
5-HT7 RECEPTOR  
  This receptor was discovered by targeted cloning strate-
gies and the localization and pharmacology of 5-HT7 recep-
tors have been the initial clues [276]. This sparked antide-
pressant screening studies with specific ligands to associate 
them with serotonergic depression. High receptor density is 
identified in the medial thalamic nuclei and related limbic 
and cortical regions of guinea pig brain [300]. The four iso-
forms of this receptor has been found to be pharmacologi-
cally equivalent and are distributed in amygdala, cortex, hip-
pocampus, thalamus, septum, hypothalamus and suprachi-
asmatic nucleus of rat brain [109]. Distribution of this recep-
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118, 300, 276, 297, 298] and it is present at intermediate 
levels in analogous human brain areas [314]. Chronic 
fluoxetine treatment down-regulated the hypothalamic 5-HT7
receptor binding sites in rats [285] and acute restraint stress 
up-regulated 5-HT7 mRNA expression in rat hippocampus 
[330] indicating the participation of 5-HT7 receptor in de-
pression. Many antidepressants have attenuated c-FOS ex-
pression which is consistent with activation of 5-HT7 recep-
tor in suprachiasmatic nucleus [219]. Prototypic antidepres-
sants have been antagonists at enteric 5-HT7 receptors acting 
through allosteric or competitive mechanisms [174]. SB-
656104-A (5-HT7 antagonist), has been found to reduce the 
time spent in REM sleep in rats [299]. Non-selective 5-HT7
agonist 5- carboxytryptamine (5-CT) induced hypothermia in 
guinea-pigs [112] and mice [108] but fails in 5-HT7 receptor 
knockout mice [108, 116]. 
  Research based on knockout and interaction studies, 
which have been conducted in the recent past, have provided 
us with substantial evidence pertaining to the role of 5-HT7
receptors. 5-HT7 knockout mice exhibit antidepressant-like 
effects in FST. Attenuation of circadian rhythm phase shifts 
to 8-OH-DPAT, observed in extra-cellular recordings from 
hypothalamic slices (5-HT7 knockout) and failure of SB-
258719 (a selective 5-HT7 receptor antagonist) as an antide-
pressant (in FST using wild mice) in light phase signifies the 
circadian cycle dependent activity [107]. Furthermore, 5-HT7
knockout mice have been screened in behavioural antide-
pressant assays namely, FST, TST and REM sleep pattern 
analysis [117], which have eventually strengthened the hy-
pothesis that inhibition of 5-HT7 receptors could be benefi-
cial in depression [118]. In a series of studies conducted in 
mice, SB-269970 decreases the duration of immobility in 
FST and TST with a characteristic ‘U’ shaped dose response 
curve [322], augments antidepressant-like effects of citalo-
pram in TST indicating a pharmacodynamic interaction [32] 
and antidepressant-like effects. As far as the REM sleep 
studies are concerned, the antidepressant-like effects of 5-
HT7 receptor antagonists are accepted with some degree of 
uncertainty since the sleep pattern observed in rats and mice 
is in contrary to what has been observed in clinical depres-
sion. 5-HT7 receptor is involved in shaping of neuronal cy-
toarchitecture, especially the hippocampus and the antide-
pressant-like behavioural effects due to 5-HT7 antagonism 
can be possibly associated with altered morphology and neu-
rogenesis [223]. Blockade of endogenous corticosterone bio-
synthesis triggers up-regulation of hippocampal 5-HT6 and 
5-HT7 mRNA expression and such an effect has been par-
tially reversed by corticosterone replacement. This up-
regulation partly explains the earlier reported therapeutic 
actions of adrenal steroid synthesis inhibitors in resistant 
depression [331]. Inhibition of the central 5-HT7 receptor 
appears to be useful in depression, supporting them as poten-
tial targets. 
OTHER PROBABLE TARGETS LINKED TO 5-HT 
SYSTEM 
Trophic Factors 
  Research has clarified the mysteries behind the BDNF 
and cAMP-CREB neurotrophic systems and has led us to a 
new way in understanding the depressive disorder simulta-
neously providing new targets for drug action [77]. While 
arriving at the molecular and cellular hypothesis of depres-
sion behind the apparent neurotransmitter theory, several 
composite intracellular mechanisms [188] which amplify the 
neurotrophic factors [75,294] eventually regulate the life, 
structure and functioning of neurons [76]. The following 
section is expected to clarify how these factors are linked to 
serotonergic system per se and to review the existence of 
other factors linked to this system.  
Brain Derived Neurotrophic Factor and Tyrosine Kinase 
B Receptor 
  Tyrosine Kinase B (TrkB) receptors are present in sero-
tonergic neurons of the raphe nuclei and their ascending pro-
jections into the dorsal hippocampus [181], neostriatum and 
nucleus accumbens [86], in rat brain. Biarylpropylsulfona-
mide AMPA receptor potentiator (LY404187) and its active 
isomer (LY451646) showed a dose and time-dependent 
modulation of BDNF and TrkB mRNA expression [180]. 
The endogenous ligand of TrkB receptor is the brain derived 
neurotrophic factor (BDNF). Central administration (in rats) 
of BDNF in Midbrain [282] and dentate gyrus of Hippocam-
pus reversed escape deficits in learned helplessness test   
and decreased duration of immobility in FST without influ-
encing locomotor status [278]. Down-regulation of the (Trk-
B)-BDNF pathway is observed in major depressive disorder 
[303]. BDNF and its receptor TrkB are modulated by   
drugs of other pharmacological classes. To mention a few,  
antidepressant-like effects of delta-opiod receptor agonist 
(+)BW373U86 [301], Deltamethrin, a pyrethroid alkaloid 
[304] were found to be mediated by BDNF., which demon-
strate the antidepressant-like effects. In the contrary, intra-
ventral tegmental area infusion of BDNF induced depression 
like states [79]. Studies targeting the TrkB receptor revealed 
that despite TrkB deficient mice are not suitable as model of 
depression [339], its over-expression in mice induces resis-
tance to behavioural despair [152].  
  Proclaimed as the ‘dynamic duo’ and together controlling 
the homeostasis against depression [201], the liaison be-
tween them BDNF and 5-HT has been strengthened by 
pharmacological [5, 77, 200, 282] and stem cell based re-
search [20, 241]. BDNF helps in the neurogenesis and neu-
roprotection of 5-HT neurons [187] and alters 5-HT receptor 
expression in different regions of mice brain [177]. 5-HT 
acting through the 5-HT1A autoreceptor, up-regulates BDNF 
which eventually acts on the TrkB receptor [88]. 5-HT2A
blockade can produce restraint stress induced BDNF sup-
pression [307, 308], correspondingly its activation increases 
the de novo BDNF mRNA synthesis [206]. A study using 
different 5-HT enhancing ligands indicated that an increase 
in 5-HT, induced a ligand dependent and region specific 
modulation of BDNF mRNA levels in rat brain [336]. 
Amitryptaline and venlafaxine treatment increased BDNF 
levels particularly in the hippocampal neurons [327] and 
similar effects were observed in other areas when treated 
with desipramine and tranylcypromine [115]. Such activation 
is due to a cascade of events involving indirect stimulation of 
neurotransmitter receptors probably via increases in endoge-
nous 5-HT levels in synapses of specific brain regions [37]. 
Fluoxetine also protected dexamethazone induced neuronal 
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dopaminergic neurons [213]. A biphasic pattern is observed 
in the BDNF gene expression that justifies the slow onset of 
action commonly observed with SSRIs [58]. Fluoxetine ex-
hibits duration of treatment dependent influence on BDNF 
expression [69]. Paroxetine, a well tolerated SSRI enhances 
synaptic plasticity in the hippocampus by boosting BDNF 
mRNA expression [196]. The recent approach in the under-
standing of antidepressant drug action involves the concepts 
of adaptation or plasticity of neural systems and BDNF is 
found to play a profound role in it [65]. Chronic restraint 
stress negatively influences the BDNF expression which was 
blocked by chronic administration of quetiapine or ven-
lafaxine, the effects being potentiated when combined [326]. 
Chronic corticosterone in addition to the influence on the 5-
HT system, has been shown to impair hippocampal BDNF 
function, which is comparable with the hippocampal atrophy 
reported in major depression [140]. Social aversion (one of 
the depression related behaviour) in mice is mainly influ-
enced by BDNF-regulated molecular pathways in the NAc 
and is counteracted by antidepressant drugs especially 
fluoxetine [24]. Though hippocampal BDNF expression was 
not influenced with wheel running behaviour (a model of 
learned helplessness) in rats [101], increased BDNF and de-
creased 5-HT turnover was observed in frontal cortex and 
hypothalamus in olfactory bulbectomised mice, a sensitive 
rodent model of hyposerotonergic depression [121]. An in
vitro study probing the drug-modulation effects in neural 
stem cells (adult rat hippocampus) indicated that imipramine 
promotes serotonergic differentiation via the modulation of 
the BDNF/MAPK/ERK pathway/Bcl-2 cascades [241]. 5-
HT1A receptor function was attenuated in the dorsal hippo-
campus of BDNF knockout mice [122]. As observed from 
the recent reports the 5-HT-BDNF interaction supports the 
monoamine theory of depression and is expected to provide 
new insights in relation to faster onset refining antidepres-
sant therapy. 
Cyclic Adenosine Monophoshate Response Element 
Binding Protein  
  Cyclic AMP response element binding protein (CREB) is 
a nuclear protein belonging to a family of leucine zipper 
transcription factors. As the name suggests, it involves the 
cAMP cascade and cAMP dependent protein kinase for acti-
vation and phosphorylation respectively [95, 209]. BDNF 
itself is a target gene regulated by CREB [56, 77, 78] and 
abolition of BDNF up-regulation has been observed in 
chronic desipramine treated CREB deficient mice [57]. It 
plays a key role in therapeutic efficacy [44] of clinically suc-
cessful serotonergic antidepressants [65, 196, 200, 208, 225, 
242] particularly, the SSRIs [230, 331]. CREB plays a key 
role in antidepressant activity of other serotonergic agents 
acting through 5-HT4, 6, 7 receptors, linked to cAMP cascade 
[77] or through 5-HT2 receptor mediated by calcium acti-
vated protein kinase [95] (Fig. 2). It is also found to play a 
role in antidepressant-like effects of various drugs of other 
pharmacological classes, such as phosphodiestrase inhibitors 
[230] and kappa-opioid receptor antagonist [183]. The 
noradrenergic mediated regulation of CREB gene is also 
reported [159]. Viral-mediated increases of CREB in nucleus 
accumbens (NAc) induced depressive states in rodent FST 
[247, 309]. Using transgenic mice it was proved that inhibi-
tion of CREB in nucleus accumbens produces antidepres-
sant-like effects in learned helplessness paradigm [228]. 
Thus CREB, is well documented as a neurotrophic factor of 
depression [221] and we presently intend to view it as down-
stream target among the various others in the serotonergic 
system. 5-HT6 (and even 5-HT7) receptors (discussed above) 
are G-protein linked and positively coupled to the adenylate 
cyclase–cAMP system. Activation of these receptors eventu-
ally lead to the triggering of CREB [215, 263, 262]. It is 
noteworthy that 5-HT induces phosphorylation of CREB in 
HEK 293 cells which have 5-HT6 and 5-HT7 and expressing 
the 5-HT transporter (SERT) [144]. Fluoxetine in combina-
tion with olanzapine supresses pCREB in rats [131]. 
Fluoxetine in addition to 5-HT release, exhibited a neuropro-
tectant effect in neural stem cell culture involving activation 
of CREB site of c-FLIP promoter region spanning nucleotide 
which may be mediated by phosphatidylinositol-3-kinase-
dependent pathway [51]. Stress is known to activate CREB 
in the nucleus accumbens and several other regions thereby 
mediating depression like behaviour [44]. Chronic Citalo-
pram treatment inhibited the CREB phosporylation in female 
rats [158] and prevented the chronic stress induced CREB 
mRNA expression in dorsal raphae nucleus of rat [1] and a 
similar effect was observed with fluoxetine [317]. Glutamate 
release has been shown to influence the 5-HT6 [70] and 5-
HT7 [32] receptor mediated activation of CREB/BDNF. 
pCREB is an immediate-early gene transcription factor asso-
ciated with changes in synaptic efficacy and neuroanatomy 
in the hippocampus, prefrontal and piriform cortex. Agents 
which ultimately activate CREB have therapeutic potential in 
depression. In short the current research has revealed intrigu-
ing aspects which imply that strategies that exploit region 
specific differences in upstream factors, or those which tar-
get specific CREB-regulated genes, can contribute to the 
treatment. 
Serotonin Transporters: 5-HTT/ SERT 
  In the last two decades, molecular biochemistry [165, 
166, 170] and extensive gene [205] based studies on differ-
ent human population [110, 150, 275, 333] using advanced 
techniques including brain imaging [43, 114, 119, 136, 253] 
have been initiated in an attempt to manage human depres-
sion. Located on the axolemma outside the synaptic junc-
tions [338], 5-HT transporters are the major sites of action of 
SSRIs. Studies using animal and in vitro simulations pertain-
ing to serotonergic depression are presented as follows. 5-
HTT was richly evident in brain stem raphae nuclei of mice 
[18], hippocampus in primates and rats and in specific 
subregions of amygdala [232, 236]. Northern blot analysis 
indicated that 5-HTT gene expression is suppressed in the 5-
HT depleted state [168] indicating a trophic role for 5-HT. 
BDNF modulates 5-HTT in B-lymphocyte cell line and rep-
resents a reliable in vitro model to examine the functional 
regulation of 5-HTT by neurotrophins [217]. Fluoxetine 
treatment down-regulates the expression of many proteins 
involved in the multiple kinase pathways determining 5-HTT 
regulation [254] and is shown to decrease the 5-HTT expres-
sion in rat dorsal raphae nucleus [233].  
  Developmental loss of 5-HTT produces altered behaviour 
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rons and decreased firing rate in the dorsal raphae nucleus 
[169]. In addition 5-HTT deficient mice have greater levels 
of extra-cellular 5-HT [198]. Repetitive electro-convulsive 
shock increases 5-HTT protein expression in the rat frontal 
cortex probably as a compensatory mechanism against the 
enhanced ECS induced 5-HT release in presynaptic terminals 
[274]. In TST, fluoxetine was ineffective as an antidepres-
sant in 5-HTT knockout mice [130] and the disruption at the 
‘C’ terminus (in 5-HTT mutant mice) leads to increased du-
ration of immobility [337]. Maternal separation induced in-
creased immobility in rat FST was mediated by decreased 
hippocampal 5-HT and raphe expression of 5-HTT mRNA 
[162]. The influence of genetic variation in 5-HTT and its 
influence on emotional traits have been recognized throwing 
new insights in understanding the genetic basis of depression 
[18, 113,114, 265]. To summarize, the blockade of re-uptake 
mechanism by inhibiting the transporter proteins increases 
the synaptic concentration of 5-HT. This has been a success-
ful strategy providing us with prototypical antidepressants.  
OTHER 5-HT RELATED MECHANISMS OF RECENT 
FOCUS 
Neurokinin Receptors and Substance P 
  Neurokinin receptor (NK-1) and its endogenous ligand 
substance P had been implicated in depression. Occurrence 
of this receptor system in the limbic regions of the brain was 
the initial spark which kindled behavioural assays with NK-1 
receptor antagonists in normal [264] and in transgenic ani-
mals [28, 266]. Substance P [129] itself is a stress mediator 
and its inhibitory effects on serotonergic neurons are medi-
ated by GABA neurons [178] and chronic antidepressant 
treatment reduces its levels in depression related brain areas 
[279]. Antagonists at central Substance P receptors (MK-
869) are reported to have therapeutic role in depression, with 
novel mechanism of action [155]. Acute and chronic treat-
ments of CP-96345 an NK-1 receptor antagonist increased 
neuronal firing in serotonergic neurons of the raphae nucleus 
and chronic treatment caused tonic activation of post-
synaptic 5-HT1A receptors [111]. NK-1 receptor antagonists 
increased neuronal firing in the norepinephrine neurons in 
locus ceruleus [202] were these receptors are most expressed 
[49] and interestingly, such an effect also influenced neu-
ronal firing in the 5-HT neurons [97, 267]. A comparative 
study in NK-1 receptor deficient mice and fluoxetine/ L-
000760735 (a substance P antagonist) treatment indicated 
that neurofilament alteration and synaptic remodeling con-
tribute to the antidepressant actions of the tested drugs [104]. 
An exhaustive enzyme, protein and molecular neurochemis-
try based study on NK-1 receptor knockout mice indicated 
many changes, analogous to antidepressant treatment [220]. 
The NK-1 receptor antagonist GR205171, (though inactive 
by itself) potentiated the antidepressant-like effects of SSRIs 
in mice FST [50]. Many reviews on NK-1/Substance P 
[266], classified the NK-1 receptor antagonists as antidepres-
sants and emphasized the requirement of specific ligands and 
battery of behavioural assays to establish such a novel class 
of antidepressants [89, 123, 124, 205, 290]. Their association 
with serotonergic system [2, 290] was also reported. In con-
trast to the preclinical studies, which have demonstrated an- 
tidepressant prospects (with an alleged involvement of the 
serotonergic system), the NK-1 receptor antagonists have 
failed in the clinical studies [2,7,261] strongly opposing the 
notion to consider them as antidepressant target.  
Corticotrophin Releasing Factor  
  These constitute a family of peptides and are involved in 
stress response. The antidepressant-like effects of CP-
154,526 (CRF-1 antagonist) were demonstrated in animal 
models viz. reversal of escape deficits in rat learned help-
lessness [189] and off late in olfactory bulbectomised rats 
[137]. Direct administration of CRF into rat dorsal raphae 
nucleus alters 5-HT release [250]. Antidepressant-like activ-
ity demonstrated by few CRF-1 receptor antagonists like R 
121919 and DMP 696 [231]. SSR125543, a selective CRF-1 
receptor antagonist increased swimming behaviour in Flind-
ers Sensitive Line rat (genetic animal model of depression) 
[235]. The rat FST, itself can model the influence of CRF on 
5-HT neurotransmission [64]. These studies advocated this 
entire pharmacological class as antidepressants. Direct ad-
ministration of CRF into rat dorsal raphae nucleus alters ex-
ploratory behaviour and serotonergic gene expression [53]. 
Hence there is a temptation to consider antagonism of CRF-1 
receptor to be beneficial in depression and the existence of 
functional interaction with serotonergic system. 
Cocaine- and Amphetamine-Regulated Transcript  
  Cocaine-and amphetamine-regulated transcript (CART), 
a vesicular neuropeptide [66] expressed in the limbic system 
[73,74,154,133] is a component of hypothalamic-pituitary 
axis [93, 287] and is associated in the pathogenesis and 
treatment of depression. It can presumably act as co-trans-
mitter/neurotransmitter to augment the antidepressant-like 
effects [237] and reversibly influence many other nuclear 
mechanisms including CRF/AVP [286], BDNF/CREB [325], 
extra cellular signal regulated kinase [160] and neurotrans-
mitters including 5-HT [277, 287, 306]. CART elevates ex-
tracellular 5-HT in both the rat dorsal raphae nucleus and 
nucleus accumbens supported by the existence of CART 
receptors responsible for the depolarization-dependent re-
lease [179]. This implies a serotonergic mechanism behind 
the antidepressant action of CART. However, the influence 
on locomotion might mask the antidepressant effects while 
screening in animal models.  
Arginine Vasopressin  
  Arginine vasopressin 1B (AVP-1B) receptor antagonist 
due to its effects on glucocorticoid and mineralocorticoid 
receptors gave the first indication involving this system in 
pathophysiology of depression [85]. SR149415, the selective 
(and orally active) AVP-1B receptor antagonist exhibited 
antidepressant-like effects in FST [102] and olfactory bul-
bectomy [137] models in rats. Fluoxetine decreased AVP 
release from rat hypothalamic organ culture [6] and attenu-
ated territorial aggression in male coral reef fish [244] and it 
was concluded that behavioural effects of SSRI (fluoxetine) 
are partly mediated through Arginine vasotocin system/ 
vasopressin [273]. Maternal separation, induced depressive 
behaviour in male rats which is mediated by changes in hy-
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research is essential to confirm its role in serotonergic de-
pression. 
Glutamate Receptor 
  The recently reported antidepressant effects of N-methy-
D-aspartate (NMDA) antagonist ketamine [23, 182, 335] had 
emphasised the importance of glutaminergic system (includ-
ing the metabotropic glutamate receptor, mGlu-R) as a can-
didate mechanism in depression. In the recent past, the in-
volvement of glutamate (excitatory neurotransmitter) path-
way [157, 163, 246, 283] and the cross talk of glutaminergic 
(NMDA) and serotonergic (5-HT1A/2A) systems (mainly in 
the prefrontal cortex) has been implicated in molecular basis 
of depression [334]. It was found that chronic antidepressant 
treatment modulates 5-HT turnover in prefrontal cortex in 
response to phencyclidine, a NMDA antagonist [71]. The 
antidepressant (and anticonvulsant) activity of NMDA recep-
tor antagonists like MK-801 was associated with increase in 
hippocampal 5-HT levels [288]. Modulation of metabotropic 
glutamate receptors have been reported to influence neuronal 
plasticity and release of neurotransmitters including 5-HT 
[288, 324]. Recognising the importance of neurogenesis in 
depression, a cell (progenitor) proliferation study indicated 
that LY379268 (mGlu2/3 receptor agonist) synergised ef-
fects of fluoxetine, implying the association of glutamate and 
serotonergic pathway in depression [199]. Based on the re-
sults from rat FST, the combination of conventional antide-
pressants (including SSRI and SNRI) and NMDA receptor 
antagonists was reported to be beneficial in depression [259]. 
It has been spectulated that differential regulation of distinct 
glutaminergic afferents on the dorsal raphae nucleus neurons 
(specific) underlies the behavioural trait of rat in the FST, the 
widely used (and discussed) model of depression [151]. The 
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) knockout mice was shown to exhibit disturbed glu-
tamate homeostasis and dercreased 5-HT levels, representing 
a model of depression and as well, the intercommunication 
of glutaminergic-serotonergic systems [52]. Hence, it was 
observed ligands of glutamate receptor (NMDA, AMPA and 
mGlu-Rs) exhibited antidepressant-like effects which are 
partly dependent on the serotonergic system. However this 
concept has been of very recent fous and much of the results 
are still awaited. 
NEURONAL PLASTICITY 
  Several reports in recent past have correlated depression 
with alteration in neuronal plasticity and recognised the role 
of serotonergic system [87, 171] and its receptor subtypes 
[67]. Neuronal structural plasticity is observed in animal 
models of depression and antidepressants are known to   
prevent it [46]. When co-administered with olanzapine, 
(fluoxetine) modulates neuronal plasticity involving the fi-
broblast growth factor-2 [190]. Fluoxetine when treated 
alone restored neuronal plasticity related hippocampal altera-
tions in diabetic mice [17] and increases the expression of 
polysialylated form of the neural cell adhesion molecule 
(PSA-NCAM) and synaptophysin (through 5-HT3 receptors), 
which are involved in synaptic remodeling and density, re-
spectively [311]. Thus we can observe that efficacy of sero-
tonergic antidepressants is attributed to modulation of neu-
ronal plasticity. 
ANTIDEPRESSANT ASSAYS 
  As we have observed, several techniques like immuno-
histochemistry and radioisotopic studies have identified the 
receptors in the dynamic neural correlates of depression and 
it is the prerogative initial step in any drug discovery pro-
gram. Subsequently, interaction studies with established an-
tidepressants, specific ligands which modulate the activity of 
target directly or indirectly and usage of knockout animals 
have been the best methods to mechanistically study the in
vivo effects of the substance under test. While subjecting a 
selective ligand to an interaction study (against depression as 
in this case), two pieces of information can be obtained, (1.) 
apparent involvement of a particular target (say a receptor or 
enzyme) in the disorder represented by the model in which it 
is screened and (2.) usefulness of the particular model in 
further screening molecules of the same (new) pharmacol-
ogical class or in short predictive validity of the model, for 
newly identified target. The present review is intended to 
serve as the design of pharmacological/genetic studies for 
screening newer serotonergic antidepressants before taking 
them to testing on humans. The test species varied from mice 
to primates. Of all behavioural tests FST, TST (tests of im-
mobility), foot shock (learned helplessness test), and reversal 
of olfactory bulbectomy induced behavioural deficits have 
been bested suited to assess the antidepressant-like effects 
(see Table 1). There is a obvious lack of selective/ specific 
ligands, as mentioned in most of the earlier review and re-
search reports and it remains a limiting factor for conducting 
interaction studies in animal models. On the other hand, in
vitro studies especially those utilizing neural stem cell cul-
ture, and B-Lymphocyte cell lines have significantly helped 
us to understand the cellular mode of action, but results from 
such studies have always been correlated with behavioural 
studies either conducted by same research group or else-
where. mRNA expression has been the central concept be-
hind the entire research carried to unravel the antidepressant 
mechanisms. While arriving at the identification of the neu-
ronal target, mRNA expression has been the first step linking 
the target and manipulative procedure.  
  Though the exact representation is questionable, it is the 
knockout animals which had provided the cardinal data and 
significance to the antidepressant screening process. The 
simplified premise for knockout studies is that neurobehav-
ioural/ biochemical/ anatomical alteration presumably no-
ticeable (in drug/situation induced conditions) in the absence 
of particular receptor is expected to furnish information on 
its (receptor) functionality as a component of the molecular 
disease state. With the advancements in biotechnology, prac-
tically every target (as observed above) can be genetically 
ablated in test systems (mainly mice). Observation of the 
entire neural picture including receptor systems, secondary 
messengers, transporter activation, neurotransmitter release, 
modulatory proteins, transcriptional factors, gene expression 
in different areas of the brain in the animals under a state of 
depression (drug induced/situational/ genetically manipu-
lated) are required for complete understanding of antidepres-
sant drug action. This can be essentially supported by the 
behavioural data. This list is not complete as other factors 
such as species variability and extrapolation of results to 
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that most of the approaches in modeling and managing de-
pression are somehow influenced by the serotonergic system. 
However, there is still a need for animal models of antide-
pressant drug action that selectively screen and support the 
involvement of the other peptides namely the CART, cal-
cineurin and AVP. 
AN IDEAL BEHAVIOURAL TEMPLATE: SSRI 
  From the above progress report we can clearly observe 
the 5-HT neurotransmitter system can be considered as the 
vital system controlling the internal homeostatic mechanism 
behind depression. This review drew our attention towards 
the ‘blockbuster’ antidepressant fluoxetine and its pharma-
cological class SSRI, which were extensively studied in the 
past 2 decades. Every proposed/established serotonergic neu-
ronal target is influenced by fluoxetine (Table 2) and almost 
all of the interaction (Pharmacological) and/or knockout (ge-
netic) studies have been conducted with fluoxetine (or other 
SSRIs), as reference standard or an agent for potentiating 
antidepressant-like effects of test compounds. The behav-
ioural effects have been attributed to various mechanisms 
including upregulation of tryptophan hydroxylase [15] and 
thus there is a temptation to devote the success of protypical 
serotonergic antidepressants like fluoxetine towards their 
action on multiple 5-HT receptors, their downstream target 
proteins (enzymes and receptors) and even on gene expres-
sion with an exceptional balance. The pressures on the anti-
depressant drug discovery (based on the current scenario) 
will include but not limited to the requirements such as early 
onset, treatment resistance, control over the entire symptom 
cloud, effectiveness in comorbid cases and most importantly, 
least adverse effects. Understanding the behavioural mani-
fests of depression as a consequence of, neurogenesis, neu-
ronal proliferation, plasticity and neurotransmitter release 
[223] would help us to overcome most of the above men-
tioned pressures, if not all. Antidepressant effects when me-
diated separately through each of the above target had a 
characteristic benefit and interaction studies designed on 
specific animal models have indicated the possible outcomes 
of such treatments in humans. In conclusion, a multi-target 
approach relying mainly on serotonergic system can be the 
dictum for developing novel antidepressant drugs. With an 
extensive usage of interaction and knockout animals based 
assays, a template for behavioural analysis (consequently 
biochemical analysis) can be designed based on SSRI (espe-
Table 1.  Serotonin Receptors, their Downstream Targets and Screening Methods: Role in Depression 
Target  Type of Modulation for Antidepres-
sant Outcome 
Method of Assessment (In Vivo/ In Vitro Animal Models) 
5HT1A  Selective Agonism (Full/Partial )  FST, TST, 8-OH-DPAT induced hyperthermia, OBX, learned helplessness, chronic 
stress, electrophysiological analysis of hippocampal slices and knockout studies. 
5HT1B  Antagonism  Schedule induced polydipsia, FST, TST, knockout studies and 5-HT release assessment 
5HT2A Antagonism  FST,TST, OBX,  mRNA expression and differential-reinforcement-of-low-rate 72-sec 
behaviour 
5HT2C  Agonism  FST, OBX, operant schedule, electroencephalography and stress induced anhedonia 
5HT3  Antagonism  FST, learned helplessness, knockout studies and electrophysiological studies. 
5HT6  Agonism  FST, TST and protein expression 
5HT7  Antagonism  FST, TST, REM pattern analysis and knockout mice 
BDNF/Trk-B  
receptor 
Upregulation  FST, TST, foot shock induced learned helplessness, stress induced depression, OBX, 
stem cell culture, mRNA levels and knockout studies 
CREB  Downregulation  FST, learned helplessness, chronic stress models, stem cell culture and knockout studies 
5-HTT/SERT Inhibiton FST, knockout studies, maternal separation induced depression, expression in B-
Lymphocyte cell line and electroconvulsive shock model 
CRF  Antagonism  FST, learned helplessness, OBX and flinders sensitive line rat. 
Substance P/NK-1 
receptor 
Antagonism  FST, neural architechture studies, protein expression and knockout mice 
AVP  Antagonism  FST, OBX, maternal separation and territorial aggression in coral reef fish 
cFOS  Supression  Stress induced models and expression studies  
CART  Activation  5-HT level assessments and protein expression studies 
Calcineurin  Activation  TST and expression studies 
The table hints the overall status of various probable targets related to the serotonergic system and the screening methods which have been used to correlate them with depression.  Assessing the Neuronal Serotonergic Target  Current Neuropharmacology, 2008, Vol. 6, No. 3    225
cially fluoxetine) drug discovery. Such an approach will 
definitely help us providing better ‘serotonergic’ antidepres-
sant molecules (safety profile dependent) for trials in the 
clinic. 
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